Nyxoah (NASDAQ:NYXH) Stock Rating Lowered by Wall Street Zen

Nyxoah (NASDAQ:NYXH) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Sunday.

Several other equities research analysts have also issued reports on NYXH. Piper Sandler reiterated an “overweight” rating and set a $6.00 price target (down from $7.00) on shares of Nyxoah in a report on Thursday. Robert W. Baird set a $2.31 price objective on Nyxoah in a report on Thursday. Weiss Ratings lowered shares of Nyxoah from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 22nd. Oppenheimer set a $4.00 target price on shares of Nyxoah in a research note on Thursday. Finally, Stifel Nicolaus decreased their target price on shares of Nyxoah from $5.00 to $3.00 and set a “hold” rating for the company in a research report on Wednesday, June 17th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Nyxoah has an average rating of “Hold” and a consensus price target of $5.26.

Nyxoah Stock Up 7.5%

Nyxoah stock opened at $1.58 on Friday. Nyxoah has a twelve month low of $1.26 and a twelve month high of $8.59. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.31 and a current ratio of 2.38. The firm has a market cap of $61.24 million, a PE ratio of -0.63 and a beta of 1.62. The firm’s 50 day moving average price is $1.63 and its two-hundred day moving average price is $2.91.

Nyxoah (NASDAQ:NYXH) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.20). The company had revenue of $8.76 million for the quarter, compared to analysts’ expectations of $8.64 million. Nyxoah had a negative net margin of 443.16% and a negative return on equity of 178.90%. On average, research analysts predict that Nyxoah will post -1.59 EPS for the current fiscal year.

Institutional Investors Weigh In On Nyxoah

Hedge funds have recently made changes to their positions in the stock. Raymond James Financial Inc. bought a new position in Nyxoah during the second quarter valued at about $70,000. Bank of America Corp DE lifted its position in shares of Nyxoah by 72.4% in the 2nd quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock worth $59,000 after acquiring an additional 3,303 shares during the period. Shay Capital LLC acquired a new stake in shares of Nyxoah during the 2nd quarter worth approximately $374,000. Citadel Advisors LLC acquired a new stake in shares of Nyxoah during the 3rd quarter worth approximately $98,000. Finally, Deutsche Bank AG increased its position in shares of Nyxoah by 40.0% during the fourth quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock valued at $161,000 after purchasing an additional 10,000 shares during the period.

Nyxoah Company Profile

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.